Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero (Nasdaq: SPRO) announced that development partner GSK resubmitted a New Drug Application to the FDA for tebipenem HBr to treat complicated urinary tract infections (cUTI), including pyelonephritis, on Dec. 19, 2025.
The NDA resubmission is supported by the Phase 3 PIVOT-PO trial that was stopped early for efficacy in May 2025 and presented at IDWeek in Oct. 2025. The filing triggers a $25 million milestone payment to Spero expected in Q1 2026. GSK holds exclusive commercialization rights outside certain Asian territories where Meiji retains rights.
Loading...
Loading translation...
Positive
$25 million milestone payment expected in Q1 2026
Phase 3 PIVOT-PO trial stopped early for efficacy (May 2025)
Exclusive global commercialization license to GSK outside certain Asian territories
Negative
FDA review and final approval pending after NDA resubmission
Meiji retains development and commercialization rights in certain Asian territories, limiting Spero/GSK geographic rights
News Market Reaction – SPRO
+1.31%
3 alerts
+1.31%Session close to close
+3.8%Peak Tracked
$129.02MMarket Cap
0.1xRel. Volume
In the Dec 19 session, SPRO gained 1.31%, reflecting a mild positive market reaction.
Argus tracked a peak move of +3.8% during that session.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This announcement confirms GSK’s NDA resubmission for tebipenem HBr in cUTI, triggering a $25 millio...
Analysis
This announcement confirms GSK’s NDA resubmission for tebipenem HBr in cUTI, triggering a $25 million milestone to Spero expected in Q1 2026. It builds directly on earlier positive Phase 3 PIVOT-PO data and IDWeek presentations. Investors following SPRO may focus on continued regulatory progress with GSK, the timing and receipt of partnership payments, and any future updates on tebipenem commercialization rights across different territories.
Announcement of late-breaking tebipenem HBr presentations at IDWeek conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent SPRO news, especially clinical and program updates, has typically led to modestly positive share reactions, while earnings and administrative updates have produced small, mixed moves without major divergences.
Recent Company History
Over the last few months, SPRO has steadily advanced tebipenem HBr. Positive Phase 3 PIVOT-PO data and IDWeek presentations in October 2025 each saw low single-digit percentage gains. Administrative and governance items, including inducement RSUs and earnings notices in November 2025, also generated modest moves. Today’s NDA resubmission and the triggered $25 million milestone extend this tebipenem regulatory trajectory, following earlier disclosures that GSK planned a U.S. filing based on the PIVOT-PO results.
Key Terms
new drug application (nda), u.s. food and drug administration (fda), carbapenem, complicated urinary tract infections (cuti), +2 more
6 terms
new drug application (nda)regulatory
"filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
u.s. food and drug administration (fda)regulatory
"resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr"
The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.
carbapenemmedical
"an investigational oral carbapenem antibiotic being developed for the treatment"
Carbapenems are a class of powerful antibiotics used to treat severe or hard-to-treat bacterial infections, often reserved when other drugs no longer work. For investors, they matter because their clinical effectiveness, regulatory approvals, and the growing problem of bacterial resistance can strongly influence a drug’s market value, hospital demand, pricing power, and the commercial prospects of companies developing or selling new or improved versions.
"antibiotic being developed for the treatment of complicated urinary tract infections (cUTI)"
Complicated urinary tract infections (cUTI) are infections of the urinary system that occur in people with underlying issues—such as anatomic abnormalities, urinary catheters, weakened immune systems, or kidney involvement—that make the infection harder to treat and more likely to recur. For investors, cUTIs matter because they drive demand for stronger or specialized antibiotics, influence clinical trial design and regulatory review, and can lead to higher healthcare costs and larger market opportunities for new therapies.
pyelonephritismedical
"for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis."
A bacterial infection of the kidney that causes inflammation, pain, fever and sometimes serious complications such as scarring or sepsis; think of it as a blockage and infection in the body's plumbing that can require urgent antibiotic treatment or hospitalization. Investors watch pyelonephritis because it can drive demand for antibiotics and diagnostics, affect clinical trial safety and regulatory reviews, and create short- or long-term costs and liability risks for healthcare companies and insurers.
biomedical advanced research and development authorityregulatory
"and Biomedical Advanced Research and Development Authority, under contract number"
A biomedical advanced research and development authority is a government agency that funds and guides the late-stage development and manufacturing of drugs, vaccines, diagnostics and other health technologies, especially those needed for public health emergencies. For investors it matters because its contracts, grants or technical support act like a bridge and safety net—reducing development risk, accelerating timelines and creating a more reliable path to revenue for companies working on critical medical products.
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.
Spero has granted GSK an exclusive license to commercialize tebipenem HBr in all territories except for certain Asian territories, where Meiji retains development and commercialization rights.
Tebipenem HBr Research Support Select tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; and Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.
About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com.
Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing of a $25 million milestone payment expected to be received by Spero in Q1 2026. In some cases, forward-looking statements may be identified by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intent," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms or other similar expressions; however, the absence of these words does not mean that statement is not forward looking . Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including whether the results of any of Spero’s clinical trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval, taking into account the effects of possible regulatory delays; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; Spero's reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero’s reliance on GSK pursuant to the exclusive GSK License Agreement to develop tebipenem HBr and GSK’s right thereunder to determine, in its sole discretion, whether to further develop tebipenem HBr; Spero's need for additional funding; Spero's ability to retain key personnel; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the Securities Exchange Commission. The forward-looking statements included in this press release represent Spero's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.
